NCT05483634

Compare Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause

Compare the Effectiveness and Side Effects of Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 40 (estimated)
• Sponsor: Mackay Memorial Hospital · Academic / Other
• Sex: Female
• Age: 45 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The definition of Genitourinary Syndrome of Menopause (GSM) is the decline of estrogens during menopause results in symptoms and clinical signs from both systems. Estrogen and other hormones production decrease after menopause because the ovaries lose their effectiveness, leading to mucosal atrophy, reduced vaginal moisture, dysuria, urgency, recurrent infection, burning, pruritus and dyspareunia. The treatment included vaginal estrogen supplement, vaginal hyaluronic acid supplement, vaginal laser, platelet rich plasma, etc. Observational cohort study will be used for study design, and questionnaire, pelvic examination, vaginal pap smear with maturation index (MI), vaginal pH, and other methods will be used for evaluation of the effectiveness and side effects.

Conditions

• Menopause
• Platelet-rich Plasma
• Estrogen Replacement Therapy
• Vaginal Atrophy

Interventions

Type	Name	Description
DRUG	Vaginal estrogen supplement	Daily vaginal estrogen supplement, then twice per week. Continue for three months.
PROCEDURE	Platelet-rich plasma injection	Monthly platelet-rich plasma injection for three months

Timeline

• Start date: 2025-12-01
• Primary completion: 2026-12-31
• Completion: 2027-06-30
• First posted: 2022-08-02
• Last updated: 2025-05-09

Locations

1 site across 1 country: Taiwan

Regulatory

• FDA-regulated drug study